Not Yet RecruitingPhase 3

The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial

Taiwan220 participantsStarted 2025-08-07

Plain-language summary

The optimal medication for women with nocturia remains uncertain. This clinical trial aimed to determine the most effective medication for women with overactive bladder and nocturia. Its primary objectives were to answer the following questions: Which medication is most effective for women with nocturia? Which medication has the least effect on heart rate variability in women with nocturia?

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * \>18 years old. * female patients with overactive bladder syndrome Exclusion Criteria: * Clinically significant dysuria (inability to urinate, difficulty urinating). * Severe stress urinary incontinence (urinary incontinence caused by coughing). * Mixed urinary incontinence mainly caused by stress urinary incontinence (urinary incontinence caused by coughing as the main symptom). * Contraindications to antimuscarinic drugs or adrenergic receptor agonists.

What they're measuring

Improvement of overactive bladder symptoms

Timeframe: 12 weeks

Trial details

NCT IDNCT07114640

SponsorFar Eastern Memorial Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-12-31

View on ClinicalTrials.gov More Urinary Bladder, Overactive trials